Karyopharm Therapeutics (KPTI) Tops Q4 EPS by 95c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of $0.46, $0.95 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $126.3 million versus the consensus estimate of $50.49 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• General Mills beats estimates as cost savings offset volumes
• KB Home (KBH) PT Lowered to $50 at RBC Capital